Switch theme
Sign up to access all valuation multiples
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
2020
64
LTM Revenue $14.1M
Last FY EBITDA -$58.0M
-$25.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xilio Therapeutics has a last 12-month revenue (LTM) of $14.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Xilio Therapeutics achieved revenue of $6.3M and an EBITDA of -$58.0M.
Xilio Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xilio Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $14.1M | XXX | $6.3M | XXX | XXX | XXX |
| Gross Profit | $14.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$58.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -914% | XXX | XXX | XXX |
| EBIT | -$58.2M | XXX | -$59.6M | XXX | XXX | XXX |
| EBIT Margin | -412% | XXX | -940% | XXX | XXX | XXX |
| Net Profit | -$56.0M | XXX | -$58.2M | XXX | XXX | XXX |
| Net Margin | -397% | XXX | -918% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Xilio Therapeutics's stock price is $1.
Xilio Therapeutics has current market cap of $55.4M, and EV of -$25.8M.
See Xilio Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$25.8M | $55.4M | XXX | XXX | XXX | XXX | $-0.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Xilio Therapeutics has market cap of $55.4M and EV of -$25.8M.
Xilio Therapeutics's trades at -4.1x EV/Revenue multiple, and 0.4x EV/EBITDA.
Equity research analysts estimate Xilio Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xilio Therapeutics has a P/E ratio of -1.0x.
See valuation multiples for Xilio Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $55.4M | XXX | $55.4M | XXX | XXX | XXX |
| EV (current) | -$25.8M | XXX | -$25.8M | XXX | XXX | XXX |
| EV/Revenue | -1.8x | XXX | -4.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBIT | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
| EV/Gross Profit | -1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.0x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXilio Therapeutics's last 12 month revenue growth is 79%
Xilio Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
Xilio Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xilio Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Xilio Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 79% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -914% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -835% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 650% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1040% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xilio Therapeutics acquired XXX companies to date.
Last acquisition by Xilio Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Xilio Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Xilio Therapeutics founded? | Xilio Therapeutics was founded in 2020. |
| Where is Xilio Therapeutics headquartered? | Xilio Therapeutics is headquartered in United States of America. |
| How many employees does Xilio Therapeutics have? | As of today, Xilio Therapeutics has 64 employees. |
| Who is the CEO of Xilio Therapeutics? | Xilio Therapeutics's CEO is Dr. Rene Russo, Pharm.D.. |
| Is Xilio Therapeutics publicy listed? | Yes, Xilio Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Xilio Therapeutics? | Xilio Therapeutics trades under XLO ticker. |
| When did Xilio Therapeutics go public? | Xilio Therapeutics went public in 2021. |
| Who are competitors of Xilio Therapeutics? | Similar companies to Xilio Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Xilio Therapeutics? | Xilio Therapeutics's current market cap is $55.4M |
| What is the current revenue of Xilio Therapeutics? | Xilio Therapeutics's last 12 months revenue is $14.1M. |
| What is the current revenue growth of Xilio Therapeutics? | Xilio Therapeutics revenue growth (NTM/LTM) is 79%. |
| What is the current EV/Revenue multiple of Xilio Therapeutics? | Current revenue multiple of Xilio Therapeutics is -1.8x. |
| Is Xilio Therapeutics profitable? | Yes, Xilio Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
